- Home
- APLM vs UGRO Comparison
APLM vs UGRO Comparison
Compare APLM & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- UGRO
- Stock Information
- Founded
- APLM 2016
- UGRO 2014
- Country
- APLM United States
- UGRO United States
- Employees
- APLM N/A
- UGRO N/A
- Industry
- APLM Blank Checks
- UGRO Industrial Specialties
- Sector
- APLM Finance
- UGRO Consumer Discretionary
- Exchange
- APLM Nasdaq
- UGRO Nasdaq
- Market Cap
- APLM 7.7M
- UGRO 8.8M
- IPO Year
- APLM N/A
- UGRO N/A
- Fundamental
- Price
- APLM $6.16
- UGRO $0.44
- Analyst Decision
- APLM Strong Buy
- UGRO Strong Buy
- Analyst Count
- APLM 2
- UGRO 1
- Target Price
- APLM $425.00
- UGRO $3.00
- AVG Volume (30 Days)
- APLM 42.6K
- UGRO 99.2K
- Earning Date
- APLM 04-15-2025
- UGRO 04-29-2025
- Dividend Yield
- APLM N/A
- UGRO N/A
- EPS Growth
- APLM N/A
- UGRO N/A
- EPS
- APLM N/A
- UGRO N/A
- Revenue
- APLM $2,101,000.00
- UGRO $59,985,133.00
- Revenue This Year
- APLM N/A
- UGRO N/A
- Revenue Next Year
- APLM N/A
- UGRO $31.25
- P/E Ratio
- APLM N/A
- UGRO N/A
- Revenue Growth
- APLM 70.54
- UGRO N/A
- 52 Week Low
- APLM $6.20
- UGRO $0.38
- 52 Week High
- APLM $63.00
- UGRO $2.16
- Technical
- Relative Strength Index (RSI)
- APLM 42.37
- UGRO 29.48
- Support Level
- APLM $6.50
- UGRO $0.39
- Resistance Level
- APLM $8.00
- UGRO $0.50
- Average True Range (ATR)
- APLM 1.36
- UGRO 0.07
- MACD
- APLM -0.22
- UGRO -0.01
- Stochastic Oscillator
- APLM 5.93
- UGRO 17.92
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.